



- (51) **International Patent Classification:**
A23L 33/12 (2016.01) *A61K 31/5575* (2006.01)
A61K 31/201 (2006.01) *A23J 7/00* (2006.01)
A61K 31/202 (2006.01) *A61K 31/685* (2006.01)
- (21) **International Application Number:** PCT/US2023/011651
- (22) **International Filing Date:** 26 January 2023 (26.01.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
- | | | |
|------------|------------------------------|----|
| 63/303,365 | 26 January 2022 (26.01.2022) | US |
| 63/303,383 | 26 January 2022 (26.01.2022) | US |
| 63/304,042 | 28 January 2022 (28.01.2022) | US |
| 63/334,065 | 22 April 2022 (22.04.2022) | US |
| 63/334,071 | 22 April 2022 (22.04.2022) | US |
| 63/340,292 | 10 May 2022 (10.05.2022) | US |
| 63/340,304 | 10 May 2022 (10.05.2022) | US |
| 63/342,509 | 16 May 2022 (16.05.2022) | US |
- (71) **Applicant:** AMARIN PHARMACEUTICALS IRELAND LIMITED [IE/IE]; 88 Harcourt Street, Dublin 2 (IE).
- (72) **Inventor; and**
- (71) **Applicant (for US only):** DUNBAR, Richard Louis [US/US]; 440 Route 22, Suite 300, Bridgewater, NJ 08807 (US).
- (72) **Inventors:** MOBERLY, James; 440 Route 22, Suite 300, Bridgewater, NJ 08807 (US). MASON, Richard, Preston; 440 Route 22, Suite 300, Bridgewater, NJ 08807 (US).
- (74) **Agent:** MCCULLOUGH, Mengke, X. et al.; Perkins Coie LLP, PO BOX 1247, Seattle, WA 98111-1247 (US).
- (81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,

(54) **Title:** LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT




FIG. 1A

(57) **Abstract:** Provided are compositions comprising one or more polyunsaturated fatty acids or derivatives thereof, a source of phospholipid, and optionally one or more additional emulsifiers, as well as methods of using the same to treat various diseases. In some embodiments, provided is a lymph-releasing composition of eicosapentaenoic acid ethyl ester (LR-EtEPA) and methods of using the same to increase EPA uptake in tissues and to treat various diseases including cardiopulmonary diseases, renal diseases, neurological diseases, and cancer.

[Continued on next page]

KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*